NCT02405013 - Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

November 30, 2017

Conditions

Hepatitis CHIV Infection

Interventions

DRUG

Sofosbuvir

Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)

DRUG

Ribavirin

Ribavirin weight-adjusted dosing (1000mg BID in patients \< 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)

DRUG

Sofosbuvir

Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)

DRUG

Ledipasvir

Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)

Trial Locations (4)

Unknown

Clinique de la Cathédrale, Yaoundé

Centre de suivi des donneurs de sang, Abidjan

CHU de Youpougon - Service de Gastro-entéro-hépatologie, Abidjan

CHU Fann, Service des Maladies Infectieuses, Dakar

All Listed Sponsors

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV